Welcome to our dedicated page for Alvotech SEC filings (Ticker: ALVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alvotech (ALVO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Alvotech files annual reports on Form 20-F and frequent current reports on Form 6-K, which together document key developments in its biosimilar business, capital structure and regulatory interactions. These filings often incorporate press releases by reference and indicate how specific information is treated for purposes of the U.S. securities laws.
Form 6-K current reports for Alvotech commonly include business updates, earnings announcements and details on regulatory milestones. Examples from recent filings include guidance ranges for revenues and adjusted EBITDA, discussion of complete response letters (CRLs) from the U.S. Food and Drug Administration for certain biosimilar candidates, and descriptions of settlement and license agreements for products such as AVT06, a proposed biosimilar to Eylea. Other 6-Ks report on European and Japanese marketing approvals for AVT03 (denosumab), AVT05 (golimumab) and AVT06 (aflibercept), as well as EMA committee opinions and court decisions related to manufacturing activities.
Alvotech’s filings also describe financing transactions, including senior unsecured convertible bonds and other debt facilities. The company explains coupon terms, conversion conditions into Swedish Depositary Receipts, use of proceeds for its research and development pipeline, and lock-up or anti-dilution provisions. These disclosures help investors understand how Alvotech funds its biosimilar development, manufacturing scale-up and global launches.
On this page, Stock Titan surfaces Alvotech’s SEC reports as they are filed with EDGAR and can pair them with AI-powered summaries that clarify complex sections. Users can quickly see which filings contain business updates, regulatory news or capital markets activity, and can also track how non-IFRS measures such as adjusted EBITDA are defined and used in the company’s disclosures. This makes it easier to interpret lengthy documents like Form 6-K exhibits and to follow the evolution of Alvotech’s biosimilar portfolio and financial profile over time.
Alvotech provided a business update and detailed new financing. The company reaffirmed its updated 2025 outlook, expecting total revenue between $570 and $600 million and adjusted EBITDA of $130 to $150 million. For 2026, it targets total revenue of $650 to $700 million and adjusted EBITDA of $180 to $220 million. This guidance factors in potential delays and Complete Response Letters from the U.S. FDA for several biosimilar candidates, assumes possible receipt of a CRL for AVT03, and is based on an assumption that U.S. marketing approvals for pending applications are received by late 2026.
The company also noted a settlement and license agreement with Regeneron Pharmaceuticals that grants AVT06, its proposed Eylea biosimilar, a U.S. license entry date in the fourth quarter of 2026, or earlier if certain conditions are met. Separately, Alvotech completed an offshore offering of $108 million senior unsecured convertible bonds due 2030, carrying a 6.875% coupon and initially convertible into Swedish Depositary Receipts at $5.9224 per SDR, a 25% premium to a $4.7379 reference price. Net proceeds are intended to be used to invest in the R&D pipeline, scale and product launches.
Alvotech reported that its product AVT03, a biosimilar to Prolia and Xgeva (both denosumab), has been approved for marketing in the European Economic Area.
This approval means Alvotech can market AVT03 across the EEA, potentially opening a new revenue stream in the osteoporosis and oncology-related bone disease markets targeted by the reference medicines. The news was communicated through a press release dated November 24, 2025, which is furnished as an exhibit to this report.
Alvotech filed a Form 6-K to share regulatory news about one of its biosimilar products. The company announced that AVT05, a biosimilar to Simponi (golimumab), has been approved for marketing in the European Economic Area. This approval means Alvotech can commercialize AVT05 in European markets covered by the EEA, potentially expanding its biosimilar portfolio reach. The filing also notes that the accompanying press release is furnished as an exhibit but is not incorporated by reference into the company’s securities registration statements.
Alvotech submitted a Form 6-K as a foreign private issuer to furnish a recent press release to investors. The filing states that, on November 12, 2025, the company issued a press release announcing its earnings for the first nine months of 2025 and providing a business update. The Form 6-K also clarifies that, except for the attached press release, the report is incorporated by reference into several existing Alvotech shelf and employee share plan registration statements, which means those registrations now formally include this new information.
Alvotech furnished a Form 6-K noting that a justice of the UK High Court rejected an injunction request from Regeneron Pharmaceuticals, joined by Bayer, relating to manufacturing activities at Alvotech’s UK contract manufacturing organization for its Eylea biosimilar candidate, AVT06. The company attached a press release as Exhibit 99.1.
The Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed.
Alvotech filed a Form 6-K reporting that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its biosimilar to Simponi (golimumab), marketed as Gobivaz. The company furnished a press release announcing the approval as Exhibit 99.1.
The report states that this Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed, under the Exchange Act.
Alvotech filed a Form 6-K noting that the U.S. Food and Drug Administration issued a complete response letter for its AVT05 Biologics License Application, covering prefilled syringe and autoinjector presentations of a proposed biosimilar to Simponi (golimumab). Following the letter, the company has reevaluated its outlook for 2025. The report incorporates the 6-K (excluding the press release) by reference into certain registration statements. The related press release, furnished as Exhibit 99.1, is not deemed filed under the Exchange Act.
Alvotech filed a Form 6-K noting organizational changes and furnishing a press release about its commercial team, including the departure of Chief Commercial Officer Anil Okay. The report states that, excluding Exhibit 99.1, this Form 6-K is incorporated by reference into the company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111, 333-281684), its F-3ASR (File No. 333-289006), and its S-8 (File No. 333-266881). Exhibit 99.1—the press release dated October 22, 2025—is furnished and not deemed filed, and it is not incorporated by reference under the Securities Act or Exchange Act.
Alvotech announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair®. The company developed AVT23 with Kashiv BioSciences LLC and has licensed commercialization rights to Advanz Pharma Holdco Limited across the European Economic Area, the UK, Switzerland, Canada, Australia and New Zealand.
This filing notifies investors that regulatory review will proceed for a late‑stage biosimilar candidate and clarifies the commercialization partner and covered territories, which could affect future revenue timing and market access if authorization is granted.
Alvotech reported regulatory progress for multiple biosimilars in September 2025. Fuji Pharma received Japanese marketing authorization for three Alvotech-developed products: AVT03 (referencing Xgeva/denosumab), AVT05 (referencing Simponi/golimumab) and AVT06 (referencing Eylea/aflibercept). Separately, the European Medicines Agency's CHMP adopted positive opinions recommending approval in the European Economic Area for AVT03 (referencing Prolia/Xgeva) and AVT05 (referencing Simponi); final European Commission decisions are pending. The company furnished press releases as Exhibits 99.1–99.3, which are provided for incorporation by reference but are not being "filed" for certain Exchange Act liabilities.